Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

A preliminary investigation of alpha-lipoic acid treatment of antipsychotic drug-induced weight gain in patients with schizophrenia.

Kim E, Park DW, Choi SH, Kim JJ, Cho HS.

J Clin Psychopharmacol. 2008 Apr;28(2):138-46. doi: 10.1097/JCP.0b013e31816777f7.

PMID:
18344723
2.

Metformin in obesity associated with antipsychotic drug administration: a pilot study.

Baptista T, Hernàndez L, Prieto LA, Boyero EC, de Mendoza S.

J Clin Psychiatry. 2001 Aug;62(8):653-5. No abstract available.

PMID:
11561940
3.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
4.

Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics.

Wang CJ, Zhang ZJ, Sun J, Zhang XB, Mou XD, Zhang XR, Shang XF, Zhang TQ.

Biol Psychiatry. 2006 Dec 15;60(12):1309-13. Epub 2006 May 2.

PMID:
16650386
5.

Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.

Murashita M, Inoue T, Kusumi I, Nakagawa S, Itoh K, Tanaka T, Izumi T, Hosoda H, Kangawa K, Koyama T.

Psychiatry Clin Neurosci. 2007 Feb;61(1):54-8.

6.

Effects of a 10-week weight control program on obese patients with schizophrenia or schizoaffective disorder: a 12-month follow up.

Chen CK, Chen YC, Huang YS.

Psychiatry Clin Neurosci. 2009 Feb;63(1):17-22. doi: 10.1111/j.1440-1819.2008.01886.x. Epub 2008 Dec 1.

7.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
8.

Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.

Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL.

J Clin Psychiatry. 2001;62 Suppl 23:45-66. Review.

9.

Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?

Le Hellard S, Theisen FM, Haberhausen M, Raeder MB, Fernø J, Gebhardt S, Hinney A, Remschmidt H, Krieg JC, Mehler-Wex C, Nöthen MM, Hebebrand J, Steen VM.

Mol Psychiatry. 2009 Mar;14(3):308-17. doi: 10.1038/sj.mp.4002133. Epub 2008 Jan 15.

PMID:
18195716
10.
11.

Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

Stahl SM, Mignon L, Meyer JM.

Acta Psychiatr Scand. 2009 Mar;119(3):171-9. doi: 10.1111/j.1600-0447.2008.01334.x. Review.

PMID:
19178394
12.

An open-label pilot trial of alpha-lipoic acid for weight loss in patients with schizophrenia without diabetes.

Ratliff JC, Palmese LB, Reutenauer EL, Tek C.

Clin Schizophr Relat Psychoses. 2015 Jan;8(4):196-200. doi: 10.3371/CSRP.RAPA.030113.

PMID:
23471087
13.

Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients.

Arranz B, Rosel P, Ramírez N, Dueñas R, Fernández P, Sanchez JM, Navarro MA, San L.

J Clin Psychiatry. 2004 Oct;65(10):1335-42.

PMID:
15491236
14.

A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain.

Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, Zhang H, Hayden D, Freudenreich O, Cather C, Evins AE, Goff DC.

Acta Psychiatr Scand. 2007 Feb;115(2):101-5.

PMID:
17244173
15.
16.

Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.

Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B.

Schizophr Res. 2009 Feb;107(2-3):115-21. doi: 10.1016/j.schres.2008.09.028. Epub 2008 Nov 6.

PMID:
18993033
17.
18.

Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.

Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Shand BI, Scott RS.

Aust N Z J Psychiatry. 2009 Jan;43(1):53-60. doi: 10.1080/00048670802534341.

PMID:
19085528
19.

Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.

Newcomer JW.

J Clin Psychiatry. 2004;65 Suppl 18:36-46. Review.

20.

Effects of second generation antipsychotics on leptin and ghrelin.

Esen-Danaci A, Sarandöl A, Taneli F, Yurtsever F, Ozlen N.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1434-8. doi: 10.1016/j.pnpbp.2008.03.015. Epub 2008 Apr 1.

PMID:
18579280

Supplemental Content

Support Center